Clinical efficacy and safety of MP-AzeFlu for the treatment of allergic rhinitis: a meta-analysis.

Abstract

OBJECTIVE:

MP-AzeFlu is a novel option for therapy of allergic rhinitis (AR). The purpose of our study was to assess the safety and efficacy of MP-AzeFlu for the treatment of allergic rhinitis, compared to placebo and azelastine monotherapy.

METHODS:

The PubMed, MEDLINE, EMBASE and Cochrane databases were comprehensively searched for all published randomized controlled trials (RCTs) of using MP-AzeFlu nasal spray on July 26, 2019. In these studies, we selected patients with clinical symptom scores. The heterogeneity of the included studies was assessed by I2.

RESULTS:

Among the 336 citations retrieved, 6 articles with over 6000 patients were finally included in the meta-analysis. The results of meta-analysis revealed that MP-AzeFlu was superior to placebo ( - 2.43 [95%CI,  - 2.73 to  - 2.14], P < 0.00001) and azelastine ( - 1.27 [95% CI,  - 1.57 to  - 0.97], P < 0.00001) in reflective total nasal symptom score. In the MP-AzeFlu group, the instantaneous total nasal symptom score ( - 2.56 [95% CI,  - 3.02 to  - 2.10], P < 0.00001) and the reflective total ocular symptom score ( - 1.22 [95% CI,  - 1.57 to  - 0.87], P < 0.00001) were significantly reduced compared to the placebo group.

CONCLUSION:

MP-AzeFlu is as safe and mild as placebo and azelastine, which also is associated with symptom relief and the improvement of quality of life in AR patients. MP-AzeFlu can provide better clinical benefits than two currently available first-line intranasal therapies. It is an ideal therapy for AR patients.

• Authors: Zhenhua Zhong, Youfang Xun, Xinyi Shi, Bing Guan, Maohua Wang
• Journal: European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (Eur Arch Otorhinolaryngol) Vol. 279 Issue 5 Pg. 2457-2464 (May 2022) ISSN: 1434-4726 [Electronic] Germany
• PMID: 34415405 (Publication Type: Journal Article, Meta-Analysis)
• Copyright: © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Chemical References

• Drug Combinations
• Nasal Sprays
• Phthalazines
• Fluticasone

Topics

• Administration, Intranasal
• Drug Combinations
• Fluticasone (therapeutic use)
• Humans
• Nasal Sprays
• Phthalazines (adverse effects)
• Rhinitis, Allergic (drug therapy)
• Treatment Outcome